Encouraging early results for redesigned Sapien valve
SAN FRANCISCO (March 10, 2013) — The new Sapien XT aortic valve showed a non-significantly lower rate of death and strokes at 30 days than the original model, and both valves demonstrated notably better short-term outcomes than seen with the Sapien system in PARTNER I, according to the first results from the PARTNER II study presented today at the American College of Cardiology's 62nd Annual Scientific Session.
PARTNER II is the first randomized clinical trial involving the Sapien XT valve and the only one that compares the new device to the original FDA-approved Sapien ...





